Phase 2 N=71 Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Myelodysplastic Syndromes · Myeloproliferative Neoplasm
Primary: Overall Survial Time — 18.3 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=266 A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
Schizophrenia · Bipolar I Disorder
Primary: Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs) — 94; 95 Participants
Phase 2 N=35 Single-agent Cobimetinib for Adults With Histiocytic Disorders
Histiocytic Disorders
Primary: Best Overall Response — 21; 5; 3; 6 Participants
Phase 2 N=119 COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
Multiple Myeloma · AL Amyloidosis · Chronic Lymphocytic Leukemia
Primary: Observed Response Rate of Anti-SARS-CoV2 Antibody Seroconversion. — 29; 28; 0 Participants
Phase 2 N=14 A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
HIV Infections
Primary: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase — 12258.5; 30833.0; 25466.0; 25689.5…
Phase 2 N=11 Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
HER2-positive Breast Cancer · Breast Adenocarcinoma · Stage II Breast Cancer AJCC v6 and v7
Primary: Percentage of Participants With Grade 3 or Greater Diarrhea — 29; 50 percentage of participants
Phase 2 N=122 A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
Pulmonary TB
Primary: Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA) — -1.93; -2.12; -2.08; -1.69 sputum log10CFU/mL
Phase 2 N=28 A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
Submental Fat
Primary: Safety: Adverse Events Follow up — 8; 4; 10; 6 Participants
Phase 2 N=200 This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Neurocognitive Function as Measured by the Neurocognitive Composite Score of the Measurement and Treatment Research to Improve Cognition in…
Phase 2 N=67 ACP-01 in Patients With Critical Limb Ischemia
Critical Limb Ischemia
Primary: Wound Size, Amputation or Survival — 12; 3 participants — p=0.258
Phase 2 N=25 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
Alzheimer's Disease
Primary: Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 1; 2 Participants
Phase 2 N=12 Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks
Flank Mass
Primary: Number of Participants With Treatment-related Adverse Events [AEs] — 12; 12; 9; 12 participants
Phase 2 N=17 BLI4700-202: A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects
Colonoscopy
Primary: Proportion of Subjects With Successful Bowel Preparation — 15 Participants
Phase 2 N=145 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by…
Phase 2 N=57 Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Central Nervous System Pathology
Primary: Overall Diagnostic Preference — 10; 34; 56; 26 Percentage of participants — p=<0.0001